In addition, as seen during clinical observations and in vitro studies, increased PIAS3 may attenuate the therapeutic effects of Tam-based hormone therapy in breast cancer patients as well as the cytotoxicity of Tam to the breast cancer cells. Here, PIAS3 is linked to breast carcinoma.